Dr. Joel Bercu PhD, MPH, DABT, Gilead Sciences - Qepler Summits And Conferences

Dr. Joel Bercu PhD, MPH, DABT

Sr. Director in the Nonclinical Safety and Pathobiology
Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines.

Dr. Joel Bercu PhD, MPH, DABT is a Sr. Director in the Nonclinical Safety and Pathobiology group at Gilead Science and has 20 years of public health / toxicology experience in pharmaceuticals. His mission while at these positions is to protect the safety of staff, patients, and the environment. He leads the Environmental and Occupational Toxicology (EOT) group at Gilead. The EOT group provides expert toxicological documentation for occupational health categorizations / occupational exposure limits, permitted / acceptable daily exposures for cleaning validation, environmental risk assessments, pharmaceutical impurity assessments (including mutagenic / carcinogenic impurities), QSAR assessments of impurities for ICH M7 compliance, deviations, leachables and extractables and excipients. The EOT group is also responsible for monitoring and reviewing toxicology tests including ecotoxicology, mutagenicity testing for impurities, and worker safety testing.

Prior to joining Gilead Sciences he has worked at Eli Lilly and Amgen. He is a member of the Society of Toxicology and the Risk Assessment, Occupational and Public Health (where he served as President), and Medical Devices specialty sections. He has had several external committees such as chairing the IQ/Drusafe Impurities Working Group and on the board of directors for the Extractables Leachables Safety Information Exchange (ELSIE). He received his BS from Texas A&M University, MPH from University of Texas – Houston School of Public Health, PhD from Indiana University, and is a Diplomate of the American Board of Toxicology (DABT). He continues to publish and present at national meetings in the field of toxicology with a focus on public health and risk assessment.

Related Sessions:

3rd Annual Genotoxic Impurities
in Pharmaceuticals Summit 2023

Genotoxic Impurities in Pharmaceuticals strategies & new methodologies: analysis, in silico & regulations.
  • 09 Mar 2023
  • Virtual,
  • Pharma
Day 1: Thursday, 09 March 2023
View Details